)The top 100 stock
market authors
selected for publication
market authors
selected for publication
dna friend » Comments » IMCL
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largestSee all
increase in followers
in the last 7 days
Fastest Climbers » -
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most activeSee all
Instabloggers.
Top Instabloggers » -
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
The "Naked" Truth About Antibodies For Cancer Therapy [View article]
DNA and AVE being the most prevalent. DNA currently owns 3 other licenses to bring new tap conjugates into phase trials. Though DNA has not yet identified the targets, patents on file suggest prostate and ovarian cancers, along with NHL being the potential targets for drugs and possibly have trials begin sometime in calendar 2008.
IMGN also likely expects its partners BIIB, CNTO, Biotest, and SAN_AVE to bring conjugates into clinic with the next 18 months.
IMGN will likely have 4-6 new drugs in the clinic by yaer end 2009.